Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
IRD on Nasdaq
Shares outstanding
71,813,353
Price per share
$3.39
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
27,812,069
Total reported value
$55,903,061
% of total 13F portfolios
0%
Share change
+8,771,323
Value change
+$17,653,005
Number of holders
58
Price from insider filings
$3.39
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PERCEPTIVE ADVISORS LLC 10% 0% $14,420,050 +$5,353,943 7,174,154 +59% Perceptive Advisors LLC 31 Dec 2025
Nantahala Capital Management, LLC 10% 0% $14,318,247 +$1,755,146 7,123,506 +14% Nantahala Capital Management, LLC 31 Dec 2025
Foundation Fighting Blindness Retinal Degeneration Fund 8% -49% $10,819,577 -$7,880,000 5,492,171 -42% Foundation Fighting Blindness Retinal Degeneration Fund 09 Dec 2025
BALYASNY ASSET MANAGEMENT L.P. 7.4% $10,271,850 5,110,373 Balyasny Asset Management L.P. 31 Dec 2025

As of 31 Dec 2025, 58 institutional investors reported holding 27,812,069 shares of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD). This represents 39% of the company’s total 71,813,353 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) together control 38% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Nantahala Capital Management, LLC 6.7% 4,781,330 +43% 0.57% $9,610,473
PERCEPTIVE ADVISORS LLC 6% 4,325,000 0% 0.16% $8,693,250
BIOS Capital Management, LP 5.1% 3,683,429 0% 9% $7,403,692
Balyasny Asset Management L.P. 3.8% 2,718,029 0.01% $5,463,238
VANGUARD GROUP INC 3.2% 2,322,897 +73% 0% $4,669,022
MILLENNIUM MANAGEMENT LLC 2.8% 2,002,550 0% $4,025,125
Mink Brook Asset Management LLC 2.3% 1,665,631 +35% 2.1% $3,347,918
Opaleye Management Inc. 1.6% 1,120,000 +1.8% 0.3% $2,251,200
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.5% 1,104,996 +16% 0% $2,221,042
Bleichroeder LP 1% 736,842 0% 0.26% $1,481,052
GEODE CAPITAL MANAGEMENT, LLC 0.7% 504,983 +7.7% 0% $1,015,726
Voss Capital, LP 0.62% 441,891 -21% 0.05% $888,201
WELLS FARGO & COMPANY/MN 0.34% 241,871 +6290% 0% $486,161
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.28% 201,635 +898% 0% $405,286
CITADEL ADVISORS LLC 0.25% 180,721 +59% 0% $363,250
STATE STREET CORP 0.24% 173,253 +19% 0% $348,239
MARSHALL WACE, LLP 0.22% 157,648 0% $316,873
TWO SIGMA INVESTMENTS, LP 0.21% 151,312 +40% 0% $304,137
BlackRock, Inc. 0.2% 141,897 +208% 0% $285,213
Creative Planning 0.18% 128,366 0% 0% $258,016
RENAISSANCE TECHNOLOGIES LLC 0.18% 126,309 -27% 0% $253,881
UBS Group AG 0.13% 89,818 +10060% 0% $180,534
OMERS ADMINISTRATION Corp 0.12% 87,900 0% $176,679
NORTHERN TRUST CORP 0.12% 87,447 +28% 0% $175,768
Texas Capital Bank Wealth Management Services Inc 0.11% 78,000 0.01% $156,780

Institutional Holders of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 27,812,069 $55,903,061 +$17,653,005 $2.01 58
2025 Q3 19,026,274 $31,911,867 +$2,765,658 $1.65 46
2025 Q2 17,503,196 $16,482,508 +$2,741,389 $0.94 43
2025 Q1 14,560,311 $14,686,745 +$11,049,669 $0.98 46
2024 Q4 3,678,848 $4,378,207 +$106,956 $1.19 42
2024 Q3 2,531,596 $3,315,513 -$283,780 $1.31 37
2024 Q2 2,696,097 $4,126,103 -$1,250,857 $1.53 37
2024 Q1 3,374,307 $6,780,798 -$925,460 $2.01 48
2023 Q4 3,712,141 $11,173,334 -$177,249 $3.01 48
2023 Q3 3,768,545 $12,624,748 +$43,437 $3.35 50
2023 Q2 3,675,838 $15,952,413 +$1,001,477 $4.34 49
2023 Q1 3,457,077 $12,962,551 +$1,457,390 $3.75 40
2022 Q4 3,099,588 $10,946,085 +$1,241,957 $3.53 34
2022 Q3 2,825,667 $5,686,000 +$828,901 $2.01 33
2022 Q2 2,407,242 $4,623,000 +$385,937 $1.92 35
2022 Q1 2,052,047 $6,623,000 -$430,212 $3.23 33
2021 Q4 2,169,473 $8,073,000 +$1,421,030 $3.73 32
2021 Q3 1,679,507 $8,621,000 +$3,116,790 $5.15 26
2021 Q2 1,038,443 $5,482,000 +$532,990 $5.28 28
2021 Q1 912,180 $5,265,087 -$7,635,114 $5.81 21
2020 Q4 2,209,512 $14,469,013 +$1,044,013 $6.52 9